Subject category:
Strategy and General Management
Published by:
NACRA - North American Case Research Association
Share a link:
https://casecent.re/p/108700
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
Syntonix Pharmaceuticals, a Boston biopharmaceutical startup company, was seeking additional financing for growth. The company, founded by Drs Richard and Laurence Blumberg, had developed and patented an improved delivery platform for long-acting biopharmaceuticals and then utilized that technology to develop new therapies to treat chronic diseases. The Transceptor(R) technology utilized a unique biological pathway to allow efficient delivery of SynFusio(TM) drug therapies. Several companies licensed the technologies in joint development deals to address several different conditions: Hemophilia B, autoimmune disorders, and infertility, as well as for use in enhanced peptide inhalation. The company had used up Angel money and Rounds A and B of venture capital financing and was looking for an additional $80 - $100 million for growth. In September 2006, Syntonix was in negotiations with a VC syndicate to gain a ‘C’ Round of funding. One member of the proposed syndicate, Biogen Idec, indicated interest in buying Syntonix outright. The Blumbergs needed to make a decision about the offer.
Subject category:
Strategy and General Management
Published by:
NACRA - North American Case Research Association
Length: 16 pages
Data source: Field research
About
Abstract
Syntonix Pharmaceuticals, a Boston biopharmaceutical startup company, was seeking additional financing for growth. The company, founded by Drs Richard and Laurence Blumberg, had developed and patented an improved delivery platform for long-acting biopharmaceuticals and then utilized that technology to develop new therapies to treat chronic diseases. The Transceptor(R) technology utilized a unique biological pathway to allow efficient delivery of SynFusio(TM) drug therapies. Several companies licensed the technologies in joint development deals to address several different conditions: Hemophilia B, autoimmune disorders, and infertility, as well as for use in enhanced peptide inhalation. The company had used up Angel money and Rounds A and B of venture capital financing and was looking for an additional $80 - $100 million for growth. In September 2006, Syntonix was in negotiations with a VC syndicate to gain a ‘C’ Round of funding. One member of the proposed syndicate, Biogen Idec, indicated interest in buying Syntonix outright. The Blumbergs needed to make a decision about the offer.
Related
Subject category:
Strategy and General Management
Published by:
NACRA - North American Case Research Association
Length: 16 pages
Data source: Field research